<DOC>
	<DOCNO>NCT00798252</DOCNO>
	<brief_summary>To determine safety maximum tolerate dose brivanib alaninate administer combination capecitabine , doxorubicin , ixabepilone , docetaxel paclitaxel chemotherapy subject advance metastatic solid tumor</brief_summary>
	<brief_title>Ascending Multiple-Dose Study Brivanib Alaninate Combination With Chemotherapeutic Agents Subjects With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Histologic/cytologic diagnosis advance metastatic solid tumor Life expectancy &gt; = 3 month Able swallow tablets/capsules Pregnant breastfeed woman No 4 previous chemotherapy regimen advance metastatic setting ( exclude prior adjuvant hormonal / immuno / biologic antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>metastatic , chemotherapy combination</keyword>
</DOC>